Considering Equity and Consumer Impacts of GLP-1 Drugs – A UBS Economist Weighs In
Health Populi
APRIL 8, 2024
As Donovan notes, “GLP-1 medication is not cheap if purchased by a private individual,” estimating that only one in five adults has insurance that would cover anti-obesity medication. It is also worth stressing that the cost of treatment is for one person, and the food spending is for a household of people,” he notes.
Let's personalize your content